# A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

> **NCT03882255** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ponesimod dose range (2 - 20 mg)
- **DRUG:** Placebo Propranolol
- **DRUG:** Propranolol 80 mg

## Key facts

- **NCT ID:** NCT03882255
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2019-08-26
- **Final completion:** 2019-08-26
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882255, "A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03882255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*